Unfortunately, even though these amyloid drugs keep on failing, the "try something else" part of the "if you fail, then you've learned something and can try something else" equation doesn't seem to really register with the industry for whatever reason. We keep pouring money into amyloid trials when it's pretty clear that there's still a lot of basic research to be done to find new leads to pursue.